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Chronic inflammation may be involved in cancer development and progression. Using 28 inflammatory-
related proteins collected from prospective blood samples from two case-control studies nested in 
the Italian component of the European Prospective Investigation into Cancer and nutrition (n = 261) 
and in the Northern Sweden Health and Disease Study (n = 402), we tested the hypothesis that 
an inflammatory score is associated with breast cancer (BC) and Β-cell Non-Hodgkin Lymphoma 
(B-cell NHL, including 68 multiple myeloma cases) onset. We modelled the relationship between 
this inflammatory score and the two cancers studied: (BC and B-cell NHL) using generalised linear 
models, and assessed, through adjustments the role of behaviours and lifestyle factors. Analyses were 
performed by cancer types pooling both populations, and stratified by cohorts, and time to diagnosis. 
Our results suggested a lower inflammatory score in B-cell NHL cases (β = −1.28, p = 0.012), and, 
to lesser, extent with BC (β = −0.96, p = 0.33) compared to controls, mainly driven by cancer cases 
diagnosed less than 6 years after enrolment. These associations were not affected by subsequent 
adjustments for potential intermediate confounders, notably behaviours. Sensitivity analyses 
indicated that our findings were not affected by the way the inflammatory score was calculated. These 
observations call for further studies involving larger populations, larger variety of cancer types and 
repeated measures of larger panel of inflammatory markers.
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Inflammation is a key pathway in many diseases including cancer1, a leading cause of death worldwide2. More 
specifically inflammation is one of the enabling hallmarks of cancer3 and is thought to influence several phases of 
cancer development including initiation and progression4 through both intrinsic (genetic events) and extrinsic 
(soluble mediators) pathways5. Epidemiological, pharmacological and genetic research provide solid evidence 
that inflammation can increase cancer risk and promote tumour progression6,7. Epidemiological studies have 
already examined the link between inflammation and risk of some cancers including bladder, oesophageal, ovar-
ian, prostate or thyroid cancer6 but also colorectal cancer8 and others7.
While breast cancer (BC) is the most commonly diagnosed cancer among women worldwide, B-cell lympho-
mas (BCLs) are the most common hematopoietic cancers in both men and women in the developed world. Few 
epidemiological studies have investigated the association between blood levels of cytokines9,10, CRP11–13 and/
or immune related factor9 and risk of BC in prospective settings and results were inconsistent9–15. Several pro-
spective studies have also examined the association between B-cell Non-Hodgkin Lymphoma (B-cell NHL) and 
circulating levels of inflammatory markers providing strong evidence of a subtle role of inflammation in B cell 
NHL development and progression16–26. These studies have suggested an increased risk of B cell NHL and/or its 
subtypes with increased blood levels of interleukin17–20,23–25, chemokines16,25, immune activation markers16,17,22 
and growth factor19. While other studies reported negative association of interleukin with risk of B cell NHL18,23.
The prevalence of these two cancers and the conflicting results regarding the role of inflammation underline 
that BC and B-cell NHL are particularly relevant to explore the role of inflammation in cancer initiation.
Previous studies generally focus on the concentration levels of individual biomarkers, and since these bio-
markers are systemic, associations between individual biomarkers and cancer may not be always apparent. 
The use of lower resolution summary scores may improve statistical power and reveal associations with cancer 
risk27,28. In the present work, we investigate inflammatory scores to ascertain their link with cancers onset. We 
used data from the EnviroGenoMarkers (EGM) project designed as two nested case-control studies including 
breast cancer (BC) and Β-cell Non-Hodgkin Lymphoma (B-cell NHL, including multiple myeloma) cases within 
two cohorts. Specifically, we constructed our inflammatory score using a large panel of cytokines, chemokines 
and growth factors measured in prospectively collected peripheral blood samples in 268 participants from the 
Italian component of the European Prospective Investigation into Cancer and Nutrition (EPIC-Italy) and 492 
participants from the Northern Sweden Health and Disease Study (NSHDS). Making the most of the EGM data-
set, we examined participant’s inflammatory status through the inflammatory score (and a corresponding unsu-
pervised alternative) in relation to cancer onset as a common mechanism in disease initiation and progression. 
These associations were investigated for each type of cancer (breast cancer and B-cell NHL separately), and after 
stratification by time-to-diagnosis (TtD).
Results
Study population. Key characteristics of the study population are reported in Table 1, participants were 
predominantly from Sweden (60.6%) with a mean age of 52.8 years (SD = 7.7). Participants from EPIC-Italy 
mostly women (74.3%) tended to report a lower education level, more physical activity, and have a higher alcohol 
consumption compared to participants from NSHDS. Our study population includes 90 breast cancer (54.4% 
from EPIC-Italy) and 248 B-cell NHL (33.8% from EPIC-Italy) prospective cases which were diagnosed from 2 
to 15.5 years after inclusion.
Pre-diagnostic inflammatory score and breast cancer. The breast cancer population includes a total 
of 167 women (56.3% from EPIC-Italy) with a slightly higher proportion of cases in both cohorts after excluding 
individuals with missing data (Supplementary Table S1). The median time to diagnosis was 5.84 years and showed 
limited heterogeneity in both cohorts (5.35 years in EPIC-Italy and 6.43 years in NSHDS). BC cases from both 
cohorts were more inactive compared to controls (p = 0.05 in EPIC-Italy and NSHDS). In NSHDS, BC cases had 
lower BMI, experienced fewer pregnancies whereas no significant differences between cases and controls for any 
of the other baseline variables investigated were observed in EPIC-Italy (Supplementary Table S1). Women with 
BC from EPIC-Italy differed from those from NSHDS by age at menarche, parity, the use of hormone replace 
therapy and their menopausal status (Supplementary Table S2).
Our analyses based on the full BC population suggested a lower inflammatory score in BC cases compared 
to controls (model 1: β = −0.96, p = 0.333, Table 2A), but that difference did not reach statistical significance. 
Consistent estimates and similar conclusions can be drawn for the analyses stratified by cohort (model 1: 
β = −1.12, p = 0.436 and β = −0.64, p = 0.640 respectively for EPIC-Italy and NSHDS, Table 2A). Adjusting for 
either behavioural, socioeconomic, or hormonal factors, or in the fully adjusted models, effect size estimates 
showed consistent signs, and associations did not reach statistical significance (p > 0.09 across all models investi-
gated, Table 2A, Supplementary Fig. S1). Stratification by time to diagnosis revealed statistically significant lower 
inflammatory score in BC cases diagnosed less than 6 years after enrolment (β = −2.88, p = 0.032, Table 2A). 
Results for each cohort separately showed consistent direction of association, but the lower inflammatory score 
in BC cases diagnosed less than 6 years after enrolment was borderline statistically significant in EPIC-Italy 
(β = −3.52, p = 0.057) and non-significant in NSHDS (β = −3.58, p = 0.196, Table 2A, Supplementary Fig. S1). 
No associations were observed in the pooled population or by cohort for BC cases diagnosed 6 years after enrol-
ment (β = −0.06, p = 0.970, Table 2A).
Analyses using the first principal component (PC1, explaining 32.6% of the variance) as an alternative inflam-
matory score showed that our conclusions were robust to our definition of the inflammatory score and we identi-
fied the same significant association indicating a lower inflammatory score in the BC cases diagnosed less than 6 
years after enrolment (β = −1.55, p = 0.029, Table 2B, Supplementary Fig. S2).
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Pre-diagnostic inflammatory score and B-cell NHL. Key characteristics of the B-cell NHL study pop-
ulation are given in Supplementary Table S3. Of the 248 β-cell malignancies cases diagnosed during follow-up, 
84 arose from the Italian population and 164 from Sweden. The median time to diagnosis was 6.09 years (5.53 
in EPIC-Italy and 6.38 in NSHDS). Cases and controls were on average 53.1 years old (Supplementary Table S3).
Our analyses of all B-cell NHL cases (i.e. pooling all histological subtypes) indicated a lower inflammatory 
score compared to controls (model 1: β = −1.28, p = 0.012 Table 3A). Consistent effect size estimates were 
observed in both cohorts separately, but the lower inflammatory score in B-cell NHL cases was only found 
statistically significant in the Swedish population (model 1: β = −0.89, p = 0.310 and β = −1.48, p = 0.019 for 
EPIC-Italy and NSHDS, respectively, Table 3A). The adjustment for socioeconomic variables, as for behaviours, 
lightly weakened these associations, but in the fully adjusted model, the lower inflammatory score in B-cell NHL 
cases was still significant in the pooled population (Table 3A – Supplementary Fig. S3).
After stratification on time to diagnosis, we observed a borderline significant lower inflammatory score in 
cases diagnosed less than 6 years after inclusion in the pooled B-cell NHL population (β = −1.27, p = 0.051, 
Table 3A). A consistent estimate of the effect size was observed in cases diagnosed more than six years after 
enrollment, without the difference reaching statistical significance (β = −1.06, p = 0.108). B-cell NHL cases diag-
noses more than 6 years after enrolment showed significantly lower inflammatory score only in the NSHDS 
samples. As before, results using PC1 as an alternative inflammatory score suggested highly consistent results 
(Table 3B, Supplementary Fig. S4).
Discussion
Our analyses identified a general lower burden of inflammation in prospective BC and B-cell NHL cancer cases. 
Although non-significant, BC cases had a lower inflammatory score compared to controls in the pooled popu-
lation and in both cohort. This difference was mainly driven by BC cases diagnosed less than 6 years after enrol-
ment, for whom the inflammatory score was significantly lower than in controls. No significant differences were 
observed after stratification by BC histological subtypes in both oestrogen receptor positive and negative BC 
(Supplementary Table S4).
All individuals 
(n = 663) EPIC-Italy (n = 261) NSHDS (n = 402)
P-valuesN
% or 
mean(sd) N
% or 
mean(sd) N
% or 
mean(sd)
Gender
Male 244 36,8% 67 25,7% 177 44,0%
<0.001
Female 419 63,2% 194 74,3% 225 56,0%
Type
Case 338 51,0% 133 51,0% 205 51,0%
—
Control 325 49,0% 128 49,0% 197 49,0%
Disease
Breast cancer (cases) 167 (90) 25,2% 94 (49) 36,0% 73 (41) 18,2%
<0.001
NHL (cases) 496 (248) 74,8% 167 (84) 64,0% 329 (164) 81,8%
Age Global 663 52.8(7.7) 261 53.5(8.1) 402 52.4(7.5) 0.430
BMI (kg/m2) Global 663 26.0(3.9) 261 25.8(3.6) 402 26.2(4.1) 0.329
Phase
1 355 53,5% 194 74,3% 161 40,1%
<0.001
2 308 46,5% 67 25,7% 241 59,9%
Center
Central 116 17,5% 116 44,4% 0 0,0%
—
North 104 15,7% 104 39,9% 0 0,0%
South 41 6,2% 41 15,7% 0 0,0%
Umea 402 60,6% 0 0,0% 402 100,0%
Smoking status
Never 326 49,2% 127 48,7% 199 49,5%
0.807Former 183 27,6% 70 26,8% 113 28,1%
Current 154 23,2% 64 24,5% 90 22,4%
Alcohol (g/day) Global 663 7.1(12.5) 261 12.5(17.6) 402 3.6(5.0) <0.001
Physical activity
Inactive 179 27,1% 70 26,8% 109 27,1%
0.007
Moderately inactive 266 40,1% 106 40,6% 160 39,8%
Moderately active 166 25,0% 54 20,7% 112 27,9%
Active 52 7,8% 31 11,9% 21 5,2%
Education
None/primary 270 40,7% 146 55,9% 124 30,8%
<0.001
Professional/technical 132 19,9% 30 11,5% 102 25,4%
Secondary 147 22,2% 55 21,1% 92 22,9%
University/college 114 17,2% 30 11,5% 84 20,9%
Inflammatory score Global 663 7.0(5.9) 261 6.8(6.1) 402 7.0(5.7) 0.244
PC1 Global 663 −0.01(3.0) 261 −0.003(3.0) 402 −0.02(3.1) 0.807
Table 1. Comparison of baseline characteristics of EPIC-Italy and NSHDS. P-values are estimated with Ӽ2 
tests, Student T-tests or Wilcoxon rank sum tests.
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B cell NHL cases also had a significantly lower inflammatory score compared to controls in the pooled popula-
tion and in NSHDS. Additional analyses showed a lower inflammatory score in all histological subtype cases, sta-
tistically significant in the largest subtype group of multiple myeloma (27.4% of B-cell NHL cases, Supplementary 
Table S5). Our results were robust to the definition of the inflammatory score and were not affected by adjusting 
for the main potential confounders.
Several limitations of this study should be considered. Our study population remains limited in size especially 
the stratified analyses by cohort, by histological subtypes and time to diagnoses. Our results showed overall sim-
ilar trends but reduced strength of associations, which might indicate limited statistical power. The two cohorts 
we used may be heterogeneous in terms of population genetics, exposure profiles, lifestyle factors and study 
design-related source of variability, explaining some result differences between the two cohorts. Only BC and 
B-cell NHL cases were included in the EGM project, hence limiting our ability to investigate the role of inflam-
mation in various cancer types. Additionally, a minimum of two years elapsed between enrolment and diagnosis. 
Since cancer development is likely to have a long latency period, over many years, we cannot rule out the presence 
of abnormal cells and cancer cases may already have been in a preclinical state at enrolment. Furthermore, we 
measured the inflammatory proteins at a single time point which may not reflect the long term inflammatory sta-
tus of an individual and does not allow us to consider the speed of cancer progression in relation to longitudinal 
Full Breast Cancer population TtD ≤ 6 years* TtD > 6 years*
Model 1 Model 1 + Behaviours Model 1 + SEP Model 1 + Hormonal Fully adjusted model Fully adjusted model Fully adjusted model
β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value
(A) Inflammatory score
All −0.96 (0.99) 0.333 −1.28 (1.01) 0.208
−1.27 
(1.02) 0.215 −1.35(1.05) 0.201 −1.72(1.09) 0.118 −2.88(1.32) 0.032 −0.06(1.43) 0.970
EPIC-
Italy
−1.12 
(1.43) 0.436 −2.03 (1.47) 0.170
−1.45 
(1.45) 0.318 −1.33(1.57) 0.400 −2.36(1.63) 0.151 −3.52(1.81) 0.057 1.03(2.67) 0.701
NSHDS −0.64 (1.37) 0.640 −0.25 (1.54) 0.871
−0.86 
(1.47) 0.558 −1.72(1.57) 0.278 −1.75 (1.88) 0.356 −3.58 (2.70) 0.196 −2.56 (1.88) 0.181
(B) Principal component 1
All −0.56 (0.53) 0.297 −0.74 (0.54) 0.175
−0.64 
(0.55) 0.241 −0.87(0.55) 0.166 −1.00(0.57) 0.083 −1.55(0.70) 0.029 −0.09(0.75) 0.906
EPIC-
Italy
−0.75 
(0.77) 0.335 −1.25 (0.81) 0.123
−0.87 
(0.79) 0.273 −0.83(0.84) 0.322 −1.30(0.88) 0.147 −1.90(1.04) 0.074 0.83(1.42) 0.564
NSHDS −0.17 (0.71) 0.810 −0.004(0.77) 0.996
−0.23 
(0.76) 0.760 −0.93 (0.81) 0.253 −0.85 (0.92) 0.361 −1.45 (1.22) 0.242 −1.29 (1.02) 0.214
Table 2. Association of pre-diagnostic inflammatory score (A) and the first PC (B) with breast cancer case/
control. Pooled cohorts (n = 167), EPIC-Italy (n = 94) and NSHDS (n = 73). Model 1 is adjusted for age and 
cohort in the overall BC population; for age and center in EPIC-Italy and age in NSHDS. β coefficient regression 
estimates inflammatory score’s (A) or PC1’s (B) difference in cases compared to controls. *Additional analyses 
stratified by time from blood collection to cases’ diagnosis included for ‘less than 6 years’ strata 49 BC cancer 
cases: 32 in EPIC-Italy and 17 in NSHDS; for ‘higher than 6 years’ strata 41 BC cancer cases: 17 in EPIC-Italy 
and 24 in NSHDS.
Full Lymphoma population TtD ≤ 6 years* TtD > 6 years*
Model 1 Model 1 + Behaviours Model 1 + SEP Fully adjusted model Fully adjusted model Fully adjusted model
β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value
(A) Inflammatory score
All −1.28 (0.51) 0.012 −1.19 (0.51) 0.021 −1.21 (0.51) 0.019 −1.11 (0.52) 0.032 −1.27 (0.65) 0.051 −1.06 (0.66) 0.108
EPIC-Italy −0.89 (0.87) 0.310 −0.93 (0.89) 0.299 −0.96 (0.88) 0.277 −1.02 (0.90) 0.258 −1.87 (1.08) 0.087 0.05 (1.20) 0.965
NSHDS −1.48 (0.63) 0.019 −1.31 (0.64) 0.040 −1.36 (0.63) 0.031 −1.19 (0.64) 0.062 −0.71 (0.82) 0.389 −1.61 (0.79) 0.043
(B) Principal component 1
All −0.77 (0.26) 0.004 −0.71 (0.26) 0.007 −0.71 (0.26) 0.007 −0.65 (0.26) 0.013 −0.76 (0.32) 0.018 −0.60 (0.33) 0.073
EPIC-Italy −0.59 (0.40) 0.138 −0.66 (0.40) 0.101 −0.62 (0.40) 0.126 −0.70 (0.40) 0.083 −1.14 (0.47) 0.017 −0.13 (0.54) 0.816
NSHDS −0.85 (0.34) 0.012 −0.73 (0.34) 0.032 −0.76 (0.34) 0.024 −0.64 (0.34) 0.059 −0.48 (0.43) 0.263 −0.82 (0.42) 0.053
Table 3. Association of pre-diagnostic inflammatory score (A) and the first PC (B) with B-cell non-Hodgkin 
lymphoma case/control. Pooled cohorts (n = 496), EPIC-Italy (n = 167) and NSHDS (n = 329) Model 1 is 
adjusted for age, gender, phase and cohort in the overall all B-cell NHL population; for age, gender, phase and 
center in EPIC-Italy and age, gender, phase in NSHDS. β coefficient regression estimates inflammatory score’s 
(A) or PC1’s (B) difference in cases compared to controls. *Additional analyses stratified by time from blood 
collection to cases’ diagnosis included for ‘less than 6 years’ strata 129 B-cell NHL cancer cases: 49 in EPIC-Italy 
and 80 in NSHDS; for ‘higher than 6 years’ strata 119 B-cell NHL cancer cases: 35 in EPIC-Italy and 84 in NSHDS.
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inflammatory burden. Finally, we cannot rule out the possibility that other factors may contribute to the associa-
tion between inflammation and cancer risk. Furthermore variables relating to the inflammatory system, such as 
infection status and/or medication could not be accounted for.
Our study has a number of strengths. First, the prospective design limits both recall and reverse causation bias 
which can be induced by the disease itself, treatments or lifestyle changes after diagnosis. We also had access to 
a wide range of information about lifestyle factors and hormonal status which allowed us to adjust for important 
potential confounders. Additionally, the availability of two cohorts allowed for independent confirmation of the 
observed signals and comparison of the inflammatory score and cancer association results between two countries. 
Moreover, compared to most previous prospective studies, we measured and combined into a score a large panel 
of inflammatory proteins to capture the inflammatory load. We know of two studies which have examined several 
markers of inflammation both individually and jointly as an inflammatory score and have reported that the use 
of a score is a robust method to explore the association between inflammatory load and future risk of cancer27,29. 
Allin et al. reported a positive association between an inflammatory score derived from three inflammatory bio-
markers (CRP, fibrinogen and whole blood leukocyte count) and future risk of colorectal, lung and BC during a 
median follow-up period of 4.8 years in a Danish general population27. To test the robustness of the definition of 
the inflammatory score, we defined, as an unsupervised alternative, a score using the first principal component 
obtained from the 28 inflammatory related proteins. Our results and conclusions remained stable with either 
score.
As a general pattern, behavioural factors and education did not seem to explain a substantial part of 
case-control differences in the inflammatory score. An unhealthy lifestyle, including smoking30, heavy drink-
ing31, physical inactivity32 and body mass index is related to higher chronic inflammation and adverse health 
outcomes33. In our study, after controlling for behavioural and education, no significant changes were observed 
in the associations indicating that these variables do not act as confounder in the observed association between 
inflammation and cancer, suggesting that inflammation may be causally linked to cancer risk.
Our study remains however restricted to a limited set of potential confounders and mediators, hence hamper-
ing the generalisability of our conclusion.
A vast majority of the studies looking at the association between inflammation and BC risk used the CRP 
and a recent meta-analysis concludes a modest statistically significant positive association between CRP concen-
tration and breast cancer risk11,34. Our results may appear to be contradictory. This may be due to our approach 
which summarises the association of 28 inflammatory related proteins with disease risk using a score to better 
capture the inflammatory status and improve statistical power but also attributable to the timing in which blood 
samples were collected and cancer diagnosed, or to other factors or confounders. Several epidemiological studies 
have explored the link between circulating marker of adiposity and inflammation in relation to BC risk with 
the underlying idea that obesity associated inflammation may increase the risk of cancer9,34–36. The release of 
inflammatory mediators may then take place in the adipocytes and might not be apparent at the same level in the 
circulatory system36,37. The time from blood collection to cancer diagnosis may change according to studies and 
influence results. In our results a lower inflammatory score in BC cases compared to controls was only observed 
in those diagnosed less than 6 years after enrolment. Early BC cases may present inflammatory differences com-
pared to those developing BC cancer later or may be already in a pre-disease stage caracterized by a lower inflam-
matory score suggesting that inflammatory status differs according to BC cancer evolution time.
Numerous studies have investigated the association between pre-diagnostic inflammation and NHL using 
cytokines, chemokines and other immune markers independently. These studies showed a deregulation of these 
biomarkers with future risk of NHL suggesting subclinical dysfunction as a consistent risk factor16–21,24,38. In a pre-
vious study in a subset of EPIC-Italy’s population, the authors reported association between lower levels of IL-2, 
INF-y and upper levels of ICAM and risk of NHL18. In another study, it has been shown that lower levels of leptin 
was associated with increased risk of NHL and upper levels of IL-10 increase risk of B-NHL; they also found no 
association between a composite score from a principal component and future risk of NHL20. A case control study 
in the PLCO trial reported an increased risk of NHL with elevated serum levels of TNF-R1 and sCD2717. Our 
results demonstrate that future cases of NHL had a lower inflammatory score compared to controls. This provides 
further support for the subtle status of deregulated immune response or failure to modulate the immune response 
appropriately in relation to NHL risk. It is also established that NHL is one of the most common malignancies 
occurring after immunosuppressive therapy use due to transplantation39,40.
Inflammation has multifaceted role in cancer including initiation, promotion and progression. Deregulation 
of biological processes can lead towards chronic inflammation or play in immunosuppressive roles. Our results 
from a case-control study nested within 2 Europeans cohorts focusing on 2 specific cancers (BC and B-cell NHL) 
suggest an association between the presence of cancer and a lower inflammatory score and support the complex 
role of chronic inflammation in cancer development. The use of the PC1 aimed to measure the inflammation var-
iability captured by the 28 proteins. These findings call for further studies to better understand how inflammatory 
changes evolve involving larger populations, larger variety of cancer types and repeated measures of larger panels 
of inflammatory markers.
Methods
Study population. The Envirogenomarkers study (EGM, www.envirogenomarkers.net) was designed as two 
nested case-control studies and includes participants from the Italian component of the European Prospective 
Investigation into Cancer and nutrition41 (EPIC-Italy) and the Northern Sweden Health and Disease Study42 
(NSHDS), which have been described previously43,44. The Envirogenomarkers project and its associated studies, 
experimental protocols and methods were approved by the Regional Ethical Review Board of the Umeå Division 
of Medical Research, for the Swedish cohort, and the Florence Health Unit Local Ethical Committee, for the 
Italian cohort. All methods were carried out in accordance with the approved guidelines.
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The EGM research project was to identify novel biomarkers associated with chronic diseases in which the 
environment might play an important role. EGM project was therefore focused on breast cancer and B-cell NHL. 
Exposure of environmental pollutants including polychlorinated biphenyls, polycyclic aromatic hydrocarbons, 
cadmium or lead were also collected.
EPIC-Italy includes 47,749 healthy participants aged 35–70 years old from 5 different areas: Turin, Varese, 
Florence, Naples, and Ragusa. Anthropometric measurement, lifestyle factors and blood samples were collected at 
recruitment (1993–1998). Standardized procedures were used to identify newly diagnosed cases of cancer based 
on automated linkages to cancer and mortality registries, municipal population offices and hospital discharge sys-
tems. In Naples follow-up information was collected through periodic personal contact. All participants signed 
a written informed consent and the ethical review boards of the International Agency for Research on Cancer, 
and of the collaborating institutions responsible for subject recruitment in each of the EPIC recruitment centers 
approved the study.
NSHDS is a prospective cohort study that included 95,000 participants from the general population from 
1990 up to January 2008. It includes three sub-cohorts, of which the largest is the Västerbotten Intervention 
Programme (VIP) that mainly recruits individuals aged 40, 50 or 60 years. At initial recruitment, subjects were 
asked to complete a self-administered questionnaire to collect demographic, medical and lifestyle information 
and a separate self-administered food frequency questionnaire. Informed consent was obtained from all par-
ticipants and a medical examination was conducted during which a blood sample was taken. Incident cancers 
occurring during follow-up were identified by linkage with the Swedish Cancer Registry and the local Northern 
Sweden Cancer Registry. NSHDS study was approved by the Local Ethical Committee in Umeå, Sweden. The 
sample selection strategy is described in Supplementary Fig. S5.
Outcome. Our study population includes breast cancer (BC) and B-cell non-Hodgkin lymphoma (B-cell 
NHL) cases who were healthy at blood collection and were clinically diagnosed from 2 (minimum chosen dura-
tion to avoid the inclusion of cancer cases at enrolment) to 15.5 years after inclusion. Only invasive breast cancer 
cases were included in the study. All eligible B-cell NHL cases, including multiple myeloma were included. For 
each case, one suitable control was selected among participants in each cohort who were alive and free of cancer 
and were matched by center, gender, date of blood collection (+/−6 months), and age at recruitment (+/−2.5 
years). We considered all B-cell NHL subtype together and in the text B-cell NHL includes multiple myeloma.
Laboratory analyses. For each participant, a blood sample was collected at enrolment and stored in cit-
rate (Italy) or EDTA (Sweden). Within two hours, plasma was separated and placed in cold storage. Biosamples 
underwent inflammatory profiling in two distinct phases and 32 of inflammation-related proteins were meas-
ured using the milliplex HCYTOMAG-60K and HSCYTMAG-60SK kits (Millipore, Billerca, MA), according to 
the manufacturer’s protocol45. Four analytes were excluded from further statistical analyses due to high rates of 
non-detection (>75%). Finally, 12 cytokines, 10 chemokines and 6 growth and angiogenic factors were measured 
for all participants (Supplementary Table S6). Protein levels below the level of detection were imputed based on a 
maximum likelihood estimation method exploiting the correlation structure across proteins to draw the missing 
values46. Levels of proteins were log-transformed to normalise their distributions. As previously proposed47, lin-
ear mixed models efficiently correct for technically-induced variation, which is potentially diluting the effects of 
interest. In practice, we adopted a two-step procedure first fitting a linear mixed model regressing protein levels 
(response) including a random intercept depending on technical covariates (microtiter plate). In a second step, 
we subtracted from the measured protein levels the random effect estimates measuring the variation linked to 
technical covariates to obtain denoised data (i.e. without the potential technical artefact)48.
Inflammatory measure. As proposed previously48, and under the working hypothesis of a consistent 
contribution of each inflammatory marker to the overall inflammatory burden, we summarized the individual 
inflammatory status as a score derived from the 28 proteins assayed: for each protein, we defined a dichotomized 
indicator: “high concentration” = 1, and “low concentration” = 0 based on the highest quartile of the denoised 
protein concentrations, and summed across the 28 proteins these binary indicators48. Principal component analy-
sis (PCA) is a mathematical algorithm that reduces the dimensionality of the data while retaining most of the var-
iation in the data set49. PCA of these 28 inflammatory markers concentrations shows that 19 PCs explained more 
than 90% of the total variation seen in the dataset (Supplementary Fig. S6). As a continuous and hypothesis-free 
alternative score, we used the scores of the first principal component (PC1, explaining 32.6% of the total variance 
of the 28 proteins).
Statistical analysis. We compared baseline characteristics of the total population and by cancer 
sub-population using the Chi-squared test or Fisher exact test for the categorical variables and T-test or Wilcoxon 
rank test for continuous variables. Categorical variables are reported as percentages while continuous variables 
are reported as mean (and standard deviation).
Our inflammatory score and its continuous alternative (PC1) were regressed against the disease outcome 
(case-control status and in BC and B-cell NHL population, separately) on the pooled population. We used the 
same model adjusting for potential confounders collected at enrolment for each type of cancer: age, gender, phase, 
cohort and center (Model 1). Potential confounders included behavioural factors: body mass index (BMI, contin-
uous variable, kg/m2); smoking status (categorical: current, former, never); alcohol consumption (continuous, g/
day); physical activity (categorical: inactive, moderately inactive, moderately active, active); and education (cate-
gorical: none/primary, professional/technical, secondary, university/college) as a proxy for socioeconomic status. 
Based on model 1, we controlled separately for behavioural factors (hereafter referred to as model 1 + behav-
iours) and for participant’s educational level (hereafter referred to as model 1 + socioeconomic position). The 
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fully adjusted model included behavioural and socioeconomic factors listed above and was additionally adjusted 
for the reproductive/hormonal variables for BC analyses only. The latter comprised menopausal status (categor-
ical: post-menopausal, pre-menopausal, unknown); contraceptive usage (categorical: yes, no); age at menarche 
(binary: ≤12 years old or >12 years old); menopausal hormone use (categorical: yes, no) and parity (quantitative 
discrete: 0, 1, 2, 3, >4).
Sensitivity analyses. We fitted our models on data for each cohort separately (EPIC-Italy and NSHDS). 
To evaluate the impact of follow-up time and consider a potential effect of the preclinical phase of the disease, 
analyses were also stratified on the time to diagnosis as defined by the time elapsed between blood collection and 
clinical diagnosis: below or above the median time to diagnosis (6 years) across the entire population of cancer 
cases. We used the same time to diagnosis cut-off (below or above 6 years) for each type of cancer since the 
median time to diagnosis vary little across cancer type (5.84 years in BC and 6.09 years in B-cell NHL). In these 
analyses, cases were compared to all controls to preserve statistical power. Analyses were also performed by BC 
and B-cell NHL histological subtypes.
Statistical analyses were performed in R v3.250 using the RStudio environment v.0.99.484. All p-values with 
p < 0.05 were considered statistically significant.
Availability of data and materials. The datasets used and/or analysed during the current study are avail-
able from the corresponding author on reasonable request.
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